ESMO 2022 Conference Coverage

 

GI
07:10

ESMO 2022 Conference Coverage

ESMO 2022 on ctDNA Dynamics, CEA, and Sites of Recurrence for the Randomised DYNAMIC Study: Adjuvant Chemotherapy Guided by ctDNA Analysis in Stage II Colon Cancer

FEATURING Jeanne Tie
  • 448 views
  • October 11, 2022
01:21

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on Characterizing the Clinico-Genomic Landscape and Outcomes of KRAS G12C-Mutated Pancreas Cancer

FEATURING Fergus Keane
  • 18 views
  • October 5, 2022
05:27

ESMO 2022 Conference Coverage

ESMO 2022 on Characterizing the Clinico-Genomic Landscape and Outcomes of KRAS G12C-Mutated Pancreas Cancer

FEATURING Fergus Keane
  • 60 views
  • October 5, 2022
01:01

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the NuTide:302 Study: NUC-3373, a ProTide Transformation of 5-FI, in Combination with Oxaliplatin (NUFOX) or Irinotecan (NUFIRI) in Advanced CRC

FEATURING Andrew Coveler
  • 14 views
  • October 3, 2022
04:14

ESMO 2022 Conference Coverage

ESMO 2022 on the NuTide:302 Study: NUC-3373, a ProTide Transformation of 5-FI, in Combination with Oxaliplatin (NUFOX) or Irinotecan (NUFIRI) in Advanced CRC

FEATURING Andrew Coveler
  • 73 views
  • October 3, 2022
09:14

ESMO 2022 Conference Coverage

ESMO 2022 on the Global Phase 3 Multiregional Clinical Trial FRESCO-2: Evaluating the Efficacy & Safety of Fruquintinib in Refractory mCRC

FEATURING Arvind Dasari
  • 254 views
  • September 30, 2022
  • 4
06:14

ESMO 2022 Conference Coverage

ESMO 2022 on the Phase 3 HIMALAYA Study: Impact of Viral Aetiology of Tremelimumab + Durvalumab in Unresectable HCC

FEATURING Stephen L. Chan
  • 79 views
  • September 30, 2022
12:50

ESMO 2022 Conference Coverage

ESMO 2022 on KRYSTAL-1: Updated Efficacy & Safety of Adagrasib With/Without Cetuximab in Advanced CRC Harboring a KRASG12C Mutation

FEATURING Samuel Klempner
  • 206 views
  • September 30, 2022
  • 1
43

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Global Phase 3 Multiregional Clinical Trial FRESCO-2: Evaluating the Efficacy & Safety of Fruquintinib in Refractory mCRC

FEATURING Arvind Dasari
  • 13 views
  • September 30, 2022
42

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Updated Analysis of DESTINY-Gastric02: A Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan in Western Patients With HER2+ Unresectable/Metastatic Gastric/Gastroesophageal Junction Cancer Who Progressed on or After Trastuzumab-Containing Regimen

FEATURING Geoffrey Ku
  • 9 views
  • September 27, 2022
05:29

ESMO 2022 Conference Coverage

ESMO 2022 Updated Analysis of DESTINY-Gastric02 Trial: T-DXd in Western Patients With HER2+ Unresectable/Metastatic GC/GEJC Who Progressed on or After Trastuzumab-Containing Regimen

FEATURING Geoffrey Ku
  • 188 views
  • September 27, 2022
  • 1
01:26

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Cetuximab vs. FOLFIRI/Cetuximab Followed by Cetuximab Alone in 1L Therapy of RAS and BRAF Wild-Type mCRC

FEATURING Armando Orlandi
  • 24 views
  • September 27, 2022
12:14

ESMO 2022 Conference Coverage

ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Cetuximab vs. FOLFIRI/Cetuximab Followed by Cetuximab Alone in 1L Therapy of RAS and BRAF Wild-Type mCRC

FEATURING Armando Orlandi
  • 219 views
  • September 27, 2022
03:47

ESMO 2022 Conference Coverage

ESMO 2022: Early Decreases in KRAS Mutant Allele Frequency Predicts Clinical Benefit to the PLK1 Inhibitor Onvansertib in Combination With FOLFIRI/Bev in 2L Treatment of mCRC

FEATURING Heinz-Josef Lenz
  • 58 views
  • September 27, 2022
01:35

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022: Beyond 1L for mCRC - Best Practices and Practical Nuances

FEATURING Timothy Price
  • 18 views
  • September 27, 2022
20:07

Timothy Price

Beyond 1L for mCRC - Best Practices and Practical Nuances

  • 311 views
  • September 27, 2022
  • 2
16:12

ESMO 2022 Conference Coverage

ESMO 2022 on Advances in HER2-Targeted Therapy or Novel Targeted Therapies for HER2+ Esophagogastric Cancers

FEATURING Kohei Shitara
  • 277 views
  • September 21, 2022
  • 4
18

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022: Real-World Monitoring of ctDNA Reliably Predicts Cancer Recurrence in Pts With Resected Stages I-III Colorectal Cancer

FEATURING Stacey Cohen
  • 17 views
  • September 21, 2022
05:42

ESMO 2022 Conference Coverage

ESMO 2022: Real-World Monitoring of ctDNA Reliably Predicts Cancer Recurrence in Pts With Resected Stages I-III Colorectal Cancer

FEATURING Stacey Cohen
  • 330 views
  • September 21, 2022
  • 1
09:24

ESMO 2022 Conference Coverage

ESMO 2022 Final Analysis of the Randomized, Phase 3 RATIONALE-301 Study: Tislelizumab vs. Sorafenib as 1L Treatment for Unresectable HCC

FEATURING Masatoshi Kudo
  • 104 views
  • September 19, 2022
04:44

ESMO 2022 Conference Coverage

ESMO 2022 on the Updated OS From the Phase 3 TOPAZ-1 Study: Durvalumab/Placebo + Gemcitabine & Cisplatin in Advanced Biliary Tract Cancer

FEATURING Do-Youn Oh
  • 167 views
  • September 19, 2022
  • 1
46

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: Pembrolizumab vs Placebo as 2L Treatment for Sorafenib-Treated aHCC

FEATURING Julien Edeline
  • 10 views
  • September 16, 2022
04:28

ESMO 2022 Conference Coverage

ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: Pembrolizumab vs. Placebo as 2L Treatment for Sorafenib-Treated aHCC

FEATURING Julien Edeline
  • 122 views
  • September 16, 2022
13:16

ESMO 2022 Conference Coverage

ESMO 2022 on the NICHE-2 Study: Neoadjuvant Immune Checkpoint Inhibition in Locally Advanced dMMR Colon Cancer

FEATURING Myriam Chalabi
  • 919 views
  • September 16, 2022
  • 6
19

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the HIPECT4 Randomized Phase 3 Study: Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Colon Cancer

FEATURING Alvaro Arjona-Sanchez
  • 22 views
  • September 16, 2022
05:02

ESMO 2022 Conference Coverage

ESMO 2022 on the HIPECT4 Randomized Phase 3 Study: Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Colon Cancer

FEATURING Alvaro Arjona-Sanchez
  • 855 views
  • September 16, 2022
  • 4
22

ESMO 2022 Conference Coverage

Lecture Summary - ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Avelumab vs. Standard 2L Treatment Chemo in mCRC Patients With Microsatellite Instability

FEATURING Julien Taieb
  • 10 views
  • September 15, 2022
06:19

ESMO 2022 Conference Coverage

ESMO 2022 on the SAMCO-PRODIGE 54 Randomised Phase II Trial: Avelumab vs. Standard 2L Treatment Chemo in mCRC Patients With Microsatellite Instability

FEATURING Julien Taieb
  • 216 views
  • September 15, 2022
  • 1